OBJECTIVE： To construct evaluation system for rational use of anti-tumor drugs and evaluate the effects. METHODS： Based on medical records of 1 927 malignant tumor patients in our hospital during Jan.-Oct. 2014， the study adopted Delphi method to determine the evaluation indexes. Referring to foreign and domestic authoritative guidelines， related literatures and drug package inserts， according to evidence-based pharmacy method， the evaluation system for rational use of anti-tumor drugs in our hospital was established from 6 aspects such as chemotherapy plan， drug dose， drug pretreatment， solvent selection， drug concentration， dosing frequency. The tumor patients receiving chemotherapy were selected from our hospital in May （pre-intervention group， 98 cases） and Dec. （post-intervention group， 87 cases） in 2015， the special comment was conducted by using above system. The utilization of anti-tumor drugs was compared between 2 groups before and after intervention. RESULTS： The unreasonable utilization rate of anti-tumor drugs was 62.2％ in pre-intervention group and 29.9％ in post-intervention group； the unreasonable rates of drug dose， drug pretreatment， drug concentration and chemotherapy plan decreased from 30.6％， 21.4％， 8.2％， 6.1％ to 12.6％， 6.9％， 4.6％， 2.3％， respectively， with statistical significance （P＜0.05）. Irrational solvent selection and dosing frequency had not been improved significantly， without statistical significance （P＞0.05）. CONCLUSIONS： The establishment of evaluation system for rational use of anti-tumor drugs can improve irrational use of anti-tumor drugs. It is certainly feasible and can provide reference for clinical pharmacists standardizing clinical use of anti-tumor drugs.